GET DAILY SIGNALSInogen (INGN) Q3 2026 Earnings: U.S. Growth Returns Amid Strategic Shift
Key Takeaways
- Inogen reported third quarter 2026 revenue of $77.2 million, down 2.4% from $79.1 million in the prior-year period.
- U.S. sales rose 3.8% to $42.2 million, marking the first year-over-year U.S. growth since the fourth quarter of 2024.
- International sales fell 9% to $34.9 million, pressured by softer capital spending among large European customers.
- Adjusted net loss from continuing operations was $0.4 million, compared with adjusted earnings of $1.2 million a year earlier.
- The company closed the divestiture of its U.S. oxygen rental business and announced a $20 million cost savings program.
- Inogen guided fourth quarter 2026 revenue to $65 million–$68 million and full-year 2026 revenue to $298 million–$301 million.
- You can find more information about Inogen's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
- Explore Trending AI Robots to see how AI-driven trading tools are navigating current market conditions.
Why This Earnings Report Matters
Inogen, a medical technology company focused on portable oxygen concentrators, released its third quarter 2026 results during a period of major strategic change. The firm has completed its exit from the U.S. oxygen rental business and is now concentrating on its core product lineup and nearby respiratory opportunities. This report provides the first detailed view of continuing operations post-divestiture, along with insights under new leadership. It stands out because it highlights whether the company can rebuild U.S. momentum, address international softness, and turn cost reductions into lasting profitability.
Breaking Down the Reported Results
Total revenue for the third quarter came in at $77.2 million, a 2.4% drop from $79.1 million a year ago. U.S. sales climbed 3.8% to $42.2 million, supported by distributor activity and new product contributions, while international sales slipped 9% to $34.9 million due to reduced capital spending by key European accounts. Portable oxygen concentrator unit volume increased nearly 6% year over year to 51,900 units. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Adjusted gross margin was 44.2%, down from 45.9% in the prior-year quarter, as lower international revenue was partly offset by manufacturing efficiencies. GAAP loss from continuing operations reached $14.8 million, including a $10.6 million non-cash goodwill impairment. On an adjusted basis, the net loss from continuing operations was $0.4 million versus adjusted earnings of $1.2 million last year. Adjusted net loss per diluted share was $0.02 compared with adjusted earnings of $0.04 a year earlier. The company closed the quarter with $97.7 million in cash, cash equivalents, marketable securities, and restricted cash, and carried no debt.
Market Reaction and Investor Sentiment
Investor response to the results will likely balance two main themes. The return of U.S. sales growth and the new cost savings initiative suggest a leaner, more focused operation. At the same time, ongoing international weakness, the impairment charge, and the revenue dip remind investors of the hurdles ahead in restoring consistent profitability. The rental business exit streamlines the model but removes a revenue source and shifts comparisons to a continuing-operations basis. Market participants will be watching whether cost controls and product momentum can counter European softness in coming quarters.
Forward Outlook and Key Factors to Monitor
Inogen guided fourth quarter 2026 revenue to $65 million–$68 million and full-year 2026 revenue from continuing operations to $298 million–$301 million. It expects a full-year 2026 adjusted net loss from continuing operations of $7 million to $8 million, indicating profitability remains an ongoing effort.
Several elements will influence the trajectory. Investors should track whether U.S. sales can maintain growth through new products and stronger distributor ties. European demand continues as a variable, with management noting that capital spending softness may persist into the fourth quarter. The $20 million cost savings program, slated to deliver annualized benefits by the end of 2027 and roughly $10 million by year-end 2026, will be monitored for bottom-line effects. Expansion into adjacent respiratory areas such as sleep and airway clearance offers longer-term potential but remains early stage. These factors together will determine if the simplified structure supports sustainable, profitable growth.
Using AI Tools in My Research Process
When evaluating names like INGN, I often rely on Tickeron’s AI Screener to quickly compare fundamentals, technical patterns, and peer performance. It helps surface relevant data points without manual effort, allowing more time to focus on the investment thesis itself. The tool integrates well with my regular review of earnings and guidance updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
INGN in upward trend: price rose above 50-day moving average on October 01, 2026
INGN moved above its 50-day moving average on October 01, 2026 date and that indicates a change from a downward trend to an upward trend. In 39 of 50 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for INGN crossed bullishly above the 50-day moving average on October 08, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 78%.
Following a +5.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where INGN advanced for three days, in 190 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
The Aroon Indicator entered an Uptrend today. In 115 of 169 cases where INGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
Bearish Trend Analysis
The 10-day RSI Indicator for INGN moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 28 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 58 cases where INGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INGN as a result. In 78 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for INGN turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 34 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
INGN broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. INGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.027) is normal, around the industry mean (4.115). P/E Ratio (-7.440) is within average values for comparable stocks, (1.586). Projected Growth (PEG Ratio) (1.290) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.393) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a medical technology company
Industry MedicalNursingServices
Advertisement